Juno Therapeutics, Inc. (JUNO): Richard Klausner , director of Juno Therapeutics, Inc. sold 12,000 shares on May 18, 2016. The Insider selling transaction was reported by the company on May 20, 2016 to the Securities and Exchange Commission. The shares were sold at $40.00 per share for a total value of $480,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 19, 2016, Richard Klausner (director) sold 12,000 shares at $43.15 per share price.On Apr 19, 2016, Bernard J Cassidy (General Counsel & Secretary) sold 3,200 shares at $43.30 per share price.Also, On Mar 30, 2016, Anthony B Evnin (director) purchased 8,000 shares at $36.58 per share price.On Mar 4, 2016, Steve Harr (officer ) sold 5,000 shares at $45.00 per share price.
Shares of Juno Therapeutics Inc (JUNO) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.38 points or -0.96% at $39.3 with 8,68,675 shares getting traded. Post opening the session at $39.31, the shares hit an intraday low of $38.22 and an intraday high of $40.53 and the price vacillated in this range throughout the day. The company has a market cap of $4,148 M and the number of outstanding shares has been calculated to be 10,55,35,597 shares. The 52-week high of Juno Therapeutics Inc is $69.28 and the 52-week low is $22.37.
Company has been under the radar of several Street Analysts.Juno Therapeutics Inc is Reiterated by Maxim Group to Buy and the brokerage firm has raised the Price Target to $ 80 from a previous price target of $78 .The Rating was issued on Apr 11, 2016.Juno Therapeutics Inc is Initiated by Citigroup to Buy and the brokerage firm has set the Price Target at $45. The Rating was issued on Feb 25, 2016.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.